Related Experiment Video
Updated: May 30, 2026

A Lip Fixation Device Facilitates Labial Salivary Gland Biopsy for Sjögren's Disease
Published on: March 6, 2026
[Etiologic treatment of sicca syndrome. What can the rheumatologist offer?]
Monica Fernández Castro1, Lucía Silva, Teresa Otón
1Servicio de Reumatología, Hospital Puerta de Hierro Majadahonda, Madrid, España.
Abstract:
No effective treatment has been documented for the glandular primary Sjögren syndrome (PSS) despite the development of oral and biologic agents that have significant activity against other autoimmune disorders. Some disease-modifying agents have been empirically evaluated for the treatment of PSS. Targeting B cells also seems very promising in SSP because of the B-cell hyperactivity recognized in this desease. This article reviews existing data on the use of disease-modifying therapy for glandular of SSP. To date, published studies and trials of oral DMARDs for the treatment of SSP have shown disappointing results. B-cell modulation is clearly a promising therapy for PSS. Many challenges in trial design and execution are evident from the studies reviewed.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents